OFEV (nintedanib) is approved in 3 indications: for the treatment of adults with IPF, for the
treatment of adults with chronic fibrosing ILDs with a progressive phenotype, and to slow the
rate of decline in pulmonary function in adult patients with SSc-ILD.¹

Efficacy data

Idiopathic Pulmonary Fibrosis

Proven to slow IPF progression by reducing lung function decline^1,2

Efficacy data

Chronic Fibrosing ILDs with a Progressive Phenotype

FDA-approved therapy for the treatment of chronic fibrosing ILDs with a progressive phenotype¹

Efficacy data

SSc-ILD

FDA-approved antifibrotic therapy to slow the rate of decline of pulmonary function in patients with SSc-ILD^1,3

Efficacy data

FDA, United States Food and Drug Administration; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; PPF, progressive pulmonary fibrosis; SSc-ILD, systemic sclerosis-associated interstitial lung disease.

References

Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079-1087.
Richeldi L, et al. N Engl J Med. 2014;370(22):2071-2082.
Distler O, et al. N Engl J Med. 2019;380(26):2518-2528.